{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:45:34Z","timestamp":1769111134999,"version":"3.49.0"},"reference-count":22,"publisher":"e-Century Publishing Corporation","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/gyhh3691","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:05:06Z","timestamp":1759039506000},"page":"7095-7101","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis of neuromyelitis optica with bilateral vision loss as initial symptom secondary to acute middle encephalitis: a report of three cases"],"prefix":"10.62347","volume":"17","author":[{"given":"Zhicong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","unstructured":"Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, Häußler V, Havla J, Hellwig K, Hümmert MW, Kleiter I, Klotz L, Krumbholz M, Kümpfel T, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Tumani H, Wildemann B and Trebst C; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol 2023; 270: 3341-3368.","journal-title":"J Neurol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"932152","DOI":"10.3389\/fimmu.2022.932152","article-title":"Th17 cells and inflammation in neurological disorders: possible mechanisms of action","volume":"13","author":"Shi","year":"2022","unstructured":"Shi Y, Wei B, Li L, Wang B and Sun M. Th17 cells and inflammation in neurological disorders: possible mechanisms of action. Front Immunol 2022; 13: 932152.","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/jnnp-2024-333790","article-title":"Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study","volume":"96","author":"Papp","year":"2025","unstructured":"Papp V, Wandall-Holm M, Bacher Svendsen K, Frederiksen J, Sellebjerg F, Illes Z and Magyari M. Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study. J Neurol Neurosurg Psychiatry 2025; 96: 184-187.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","unstructured":"Bagherieh S, Afshari-Safavi A, Vaheb S, Kiani M, Ghaffary EM, Barzegar M, Shaygannejad V, Zabeti A and Mirmosayyeb O. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Neurol Sci 2023; 44: 1905-1915.","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"938492","DOI":"10.3389\/fimmu.2022.938492","article-title":"Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: a case report","volume":"13","author":"Bu","year":"2022","unstructured":"Bu Y, Liu H, Qian X, Sun F, Li C and Han J. Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: a case report. Front Immunol 2022; 13: 938492.","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"8946","DOI":"10.3390\/ijms22168946","article-title":"Th17-related cytokines as potential discriminatory markers between neuromyelitis optica (Devic’s Disease) and multiple sclerosis-a review","volume":"22","author":"Maciak","year":"2021","unstructured":"Maciak K, Pietrasik S, Dziedzic A, Redlicka J, Saluk-Bijak J, Bijak M, Włodarczyk T and Miller E. Th17-related cytokines as potential discriminatory markers between neuromyelitis optica (Devic’s Disease) and multiple sclerosis-a review. Int J Mol Sci 2021; 22: 8946.","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"DM","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE and Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-189.","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and anti-MOG syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","unstructured":"Lana-Peixoto MA and Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines 2019; 7: 42.","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK and Vaknin-Dembinsky A. International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm 2023; 10: e200124.","DOI":"10.1212\/NXI.0000000000200124"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Li SY, Peng CX, Zuo HX, Lin Q, Yu JF, Liu W, Li L and Shi W. Evaluating the clinical characteristics and ophthalmic manifestations in children and adolescents with acquired demyelinating disorders in China. Br J Hosp Med (Lond) 2025; 86: 1-12.","DOI":"10.12968\/hmed.2024.0555"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-0043-1761432","article-title":"Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents","volume":"81","author":"RB","year":"2023","unstructured":"Paolilo RB, Paz JAD, Apóstolos-Pereira SL, Rimkus CM, Callegaro D and Sato DK. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arq Neuropsiquiatr 2023; 81: 201-211.","journal-title":"Arq Neuropsiquiatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"746959","DOI":"10.3389\/fneur.2021.746959","article-title":"Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2021","unstructured":"Liu J, Tan G, Li B, Zhang J, Gao Y, Cao Y, Jia Z and Sugimoto K. Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity: a systematic review and meta-analysis. Front Neurol 2021; 12: 746959.","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ana.26623","article-title":"Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants","volume":"93","author":"Yin","year":"2023","unstructured":"Yin HX, Wang YJ, Liu MG, Zhang DD, Ren HT, Mao ZF, Zhang Y, Peng B, Cui LY and Xu Y. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants. Ann Neurol 2023; 93: 1069-1081.","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"873576","DOI":"10.3389\/fimmu.2022.873576","article-title":"Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models","volume":"13","author":"Wang","year":"2022","unstructured":"Wang L, Du L, Li Q, Li F, Wang B, Zhao Y, Meng Q, Li W, Pan J, Xia J, Wu S, Yang J, Li H, Ma J, ZhangBao J, Huang W, Chang X, Tan H, Yu J, Zhou L, Lu C, Wang M, Dong Q, Lu J, Zhao C and Quan C. Neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody: outcome prediction models. Front Immunol 2022; 13: 873576.","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/jnnp-2024-334090","article-title":"Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: a multicentre study","volume":"96","author":"Siriratnam","year":"2025","unstructured":"Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S and Monif M; MSBASE study group. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: a multicentre study. J Neurol Neurosurg Psychiatry 2025; 96: 361-369.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1559118","DOI":"10.3389\/fneur.2025.1559118","article-title":"Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab","volume":"16","author":"Zhou","year":"2025","unstructured":"Zhou J, Yang X, Wang X, Li B, Xu Y, Zhang H, Zhu Y, Wang X and Feng J. Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Front Neurol 2025; 16: 1559118.","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaneurol.2024.4400","article-title":"Blood-based biomarkers for identifying disease activity in AQP4-IgG-Positive neuromyelitis optica spectrum disorder","volume":"82","author":"SH","year":"2025","unstructured":"Kim SH, Gomes ABAGR, Schindler P, Hyun JW, Kim KH, Lee DE, Schoeps VA, Matos AMB, Mendes NT, Apóstolos-Pereira SLD, Callegaro D, Lerner J, Benkert P, Kuhle J, Ruprecht K, Paul F, Pröbstel AK and Kim HJ. Blood-based biomarkers for identifying disease activity in AQP4-IgG-Positive neuromyelitis optica spectrum disorder. JAMA Neurol 2025; 82: 168-175.","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"103030","DOI":"10.1016\/j.msard.2021.103030","article-title":"The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","unstructured":"Li X, Zhang C, Jia D, Fan M, Li T, Tian DC, Liu Y and Shi FD. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 2021; 53: 103030.","journal-title":"Mult Scler Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"103761","DOI":"10.1016\/j.autrev.2025.103761","article-title":"Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: how to correctly diagnose the two","volume":"24","author":"Chu","year":"2025","unstructured":"Chu F, Shi M and Zhu J. Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: how to correctly diagnose the two. Autoimmun Rev 2025; 24: 103761.","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3988\/jcn.2022.18.4.453","article-title":"Disease Course and outcomes in patients with the limited form of neuromyelitis optica spectrum disorders and negative AQP4-IgG serology at disease onset: a prospective cohort study","volume":"18","author":"Chen","year":"2022","unstructured":"Chen X, Zhou J, Li R, Zhang B, Wang Y, Zhong X, Shu Y, Chang Y and Qiu W. Disease Course and outcomes in patients with the limited form of neuromyelitis optica spectrum disorders and negative AQP4-IgG serology at disease onset: a prospective cohort study. J Clin Neurol 2022; 18: 453-462.","journal-title":"J Clin Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.msard.2018.10.108","article-title":"Neuromyelitis optica spectrum disorders (NMO-SD) in a sub-saharan africa country: a preliminary study of sixteen senegalese cases","volume":"27","author":"NM","year":"2019","unstructured":"Gaye NM, Fall M, Diop AM, Dadah SML, Ka M, Cissé O, Diagne NS, Diop-Sène MS, Sow AD, Basse-Faye AM, Sarr MM, Touré K, Seck LB, Ndiaye M and Diop AG. Neuromyelitis optica spectrum disorders (NMO-SD) in a sub-saharan africa country: a preliminary study of sixteen senegalese cases. Mult Scler Relat Disord 2019; 27: 179-183.","journal-title":"Mult Scler Relat Disord"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Sokhi D, Suleiman A, Manji S, Hooker J and Mativo P. Cases of neuromyelitis optica spectrum disorder from the East Africa region, highlighting challenges in diagnostics and healthcare access. eNeurologicalSci 2021; 23; 22: 100320.","DOI":"10.1016\/j.ensci.2021.100320"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0165823.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:13:08Z","timestamp":1769051588000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0165823.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/gyhh3691","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}